Bristol-Myers Squibb Co
DUS:BRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bristol-Myers Squibb Co
DUS:BRM
|
US |
|
B
|
Byd Electronic (International) Co Ltd
F:4BY
|
CN |
|
S
|
Standard Chartered PLC
F:STD
|
UK |
Intrinsic Value
The intrinsic value of 
Bristol-Myers Squibb Co (BRM) under the Base Case is 50.12 EUR per share.
Compared with the current market price of 54.05 EUR, the stock appears
Overvalued by 7% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Bristol-Myers Squibb Does
Bristol-Myers Squibb is a global drugmaker that develops, manufactures, and sells prescription medicines for serious diseases. Its products are used mainly in cancer, heart disease, immune disorders, and blood diseases. The company spends heavily on research, clinical trials, and regulatory approval because its business depends on turning scientific discoveries into approved medicines.
- Headquarters
- United States of America US
- Employees
- 32 500
- IPO date
- Mar 17, 1980
Bristol-Myers Squibb has a wide economic moat
Patents and legal protection against copies prevent rivals from freely reproducing Bristol Myers Squibb’s protected medicines and competing mainly on price. These protections cover a broad range of treatments, including cancer drugs and medicines for heart and immune conditions, rather than depending on a single discovery.
Read the full moat analysis
Revenue & Expenses Breakdown
Bristol-Myers Squibb Co
Earnings Waterfall
Bristol-Myers Squibb Co
The intrinsic value for Bristol-Myers Squibb Co (BRM) under the Base Case is 50.12 EUR.
Compared with the current market price of 54.05 EUR, the stock appears Overvalued by 7% .